A detailed history of Prelude Capital Management, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 4,833 shares of ALNY stock, worth $1.16 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
4,833
Previous 4,833 -0.0%
Holding current value
$1.16 Million
Previous $1.33 Million -0.0%
% of portfolio
0.08%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $23,381 - $28,701
-100 Reduced 2.03%
4,833 $1.33 Million
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $286,333 - $493,506
-1,998 Reduced 28.83%
4,933 $1.2 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $772,840 - $1.05 Million
5,275 Added 318.54%
6,931 $1.04 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $250,734 - $325,519
1,656 New
1,656 $316,000
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $326,596 - $421,127
1,788 New
1,788 $358,000
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $758,707 - $995,173
-4,755 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $544,727 - $666,605
-3,209 Reduced 40.29%
4,755 $898,000
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $799,564 - $1.1 Million
-6,216 Reduced 43.84%
7,964 $1.35 Million
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $1.8 Million - $2.49 Million
14,180 New
14,180 $2 Million
Q4 2020

Feb 16, 2021

SELL
$122.97 - $147.0 $151,253 - $180,810
-1,230 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $101,314 - $138,349
-836 Reduced 40.46%
1,230 $179,000
Q2 2020

Aug 14, 2020

BUY
$104.21 - $156.44 $215,297 - $323,205
2,066 New
2,066 $306,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.